AU2003292120B2 - New synergistic combination comprising roflumilast and formoterol - Google Patents

New synergistic combination comprising roflumilast and formoterol Download PDF

Info

Publication number
AU2003292120B2
AU2003292120B2 AU2003292120A AU2003292120A AU2003292120B2 AU 2003292120 B2 AU2003292120 B2 AU 2003292120B2 AU 2003292120 A AU2003292120 A AU 2003292120A AU 2003292120 A AU2003292120 A AU 2003292120A AU 2003292120 B2 AU2003292120 B2 AU 2003292120B2
Authority
AU
Australia
Prior art keywords
roflumilast
formoterol
acceptable salt
pharmacologically acceptable
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003292120A
Other languages
English (en)
Other versions
AU2003292120A1 (en
Inventor
Rolf Beume
Daniela Bundschuh
Norbert Kolassa
Degenhard Marx
Christian Wiemar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2003292120A1 publication Critical patent/AU2003292120A1/en
Assigned to NYCOMED GMBH reassignment NYCOMED GMBH Request for Assignment Assignors: ALTANA PHARMA AG
Application granted granted Critical
Publication of AU2003292120B2 publication Critical patent/AU2003292120B2/en
Assigned to TAKEDA GMBH reassignment TAKEDA GMBH Request to Amend Deed and Register Assignors: NYCOMED GMBH
Assigned to TAKEDA GMBH reassignment TAKEDA GMBH Request to Amend Deed and Register Assignors: TAKEDA GMBH
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB Request for Assignment Assignors: TAKEDA GMBH
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2003292120A 2002-11-27 2003-11-26 New synergistic combination comprising roflumilast and formoterol Ceased AU2003292120B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02026505 2002-11-27
EP02026505.4 2002-11-27
PCT/EP2003/013275 WO2004047829A1 (en) 2002-11-27 2003-11-26 New synergistic combination comprising roflumilast and formoterol

Publications (2)

Publication Number Publication Date
AU2003292120A1 AU2003292120A1 (en) 2004-06-18
AU2003292120B2 true AU2003292120B2 (en) 2010-01-21

Family

ID=32338002

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003292120A Ceased AU2003292120B2 (en) 2002-11-27 2003-11-26 New synergistic combination comprising roflumilast and formoterol

Country Status (31)

Country Link
US (1) US20060142308A1 (enExample)
EP (1) EP1567139B1 (enExample)
JP (1) JP2006508994A (enExample)
KR (1) KR101071798B1 (enExample)
CN (1) CN100346777C (enExample)
AT (1) ATE399543T1 (enExample)
AU (1) AU2003292120B2 (enExample)
BR (1) BR0316451A (enExample)
CA (1) CA2506962C (enExample)
CO (1) CO5690570A2 (enExample)
CY (1) CY1110369T1 (enExample)
DE (1) DE60321953D1 (enExample)
DK (1) DK1567139T3 (enExample)
EA (1) EA009935B1 (enExample)
ES (1) ES2309357T3 (enExample)
HR (1) HRP20050579B1 (enExample)
IL (1) IL168308A (enExample)
IS (1) IS2575B (enExample)
MA (1) MA27539A1 (enExample)
ME (1) ME00489B (enExample)
MX (1) MXPA05005437A (enExample)
NO (1) NO334247B1 (enExample)
NZ (1) NZ540659A (enExample)
PL (1) PL216752B1 (enExample)
PT (1) PT1567139E (enExample)
RS (1) RS51081B (enExample)
SI (1) SI1567139T1 (enExample)
TN (1) TNSN05131A1 (enExample)
UA (1) UA83018C2 (enExample)
WO (1) WO2004047829A1 (enExample)
ZA (1) ZA200503308B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DK1606261T3 (da) 2003-03-10 2010-01-18 Nycomed Gmbh Hidtil ukendt fremgangsmåde til fremstilling af roflumilast
AU2006224619B2 (en) * 2005-03-16 2012-06-07 Takeda Gmbh Taste masked dosage form containing roflumilast
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
ES2378281T3 (es) * 2006-07-05 2012-04-10 Nycomed Gmbh Combinación de atorvastatina con un inhibidor de fosfodiesterasa 4 para el tratamiento de neumopatías inflamatorias
WO2013077830A1 (en) * 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
US20130172303A1 (en) * 2012-01-03 2013-07-04 Forest Laboratories Holdings Ltd. Roflumilast compositions for the treatment of copd
LT2948148T (lt) * 2013-01-28 2020-12-28 Incozen Therapeutics Pvt. Ltd. Autoimuninių, kvėpavimo ir uždegiminių sutrikimų gydymo būdai, įkvėpiant roflumilasto n-oksidą
CN104800214A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入气雾剂复方及制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
WO1998035683A1 (en) * 1997-02-17 1998-08-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Compositions for the treatment of ards or irds containing 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide and lung surfactant
WO2001013953A2 (en) * 1999-08-21 2001-03-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
US6288118B1 (en) * 1998-08-26 2001-09-11 Smithkline Beecham Corporation Therapies for treating pulmonary diseases
WO2002066422A1 (en) * 2001-02-14 2002-08-29 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
WO2002076933A1 (en) * 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59410119D1 (de) * 1993-07-02 2002-06-20 Byk Gulden Lomberg Chem Fab Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
DK0975347T3 (da) * 1997-02-28 2008-06-16 Nycomed Gmbh Synergistisk kombination af PDE-inhibitorer og adenylatcyclase-agonister eller guanylcyclyseagonister
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
US6303145B2 (en) * 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
WO2002088167A1 (en) * 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
WO1998035683A1 (en) * 1997-02-17 1998-08-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Compositions for the treatment of ards or irds containing 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide and lung surfactant
US6288118B1 (en) * 1998-08-26 2001-09-11 Smithkline Beecham Corporation Therapies for treating pulmonary diseases
WO2001013953A2 (en) * 1999-08-21 2001-03-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
WO2002066422A1 (en) * 2001-02-14 2002-08-29 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
WO2002076933A1 (en) * 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Curr Opin Investig Drugs, 2002, 3(8): 1165-70 *
Eur Resp J, 1999, 13(5): 1103-8 *
Expert Opin Ther Pat, 2002, 12(1): 53-63 *

Also Published As

Publication number Publication date
CY1110369T1 (el) 2015-04-29
AU2003292120A1 (en) 2004-06-18
RS20050382A (sr) 2007-08-03
DE60321953D1 (de) 2008-08-14
NO334247B1 (no) 2014-01-20
CO5690570A2 (es) 2006-10-31
WO2004047829A1 (en) 2004-06-10
ES2309357T3 (es) 2008-12-16
NZ540659A (en) 2007-05-31
CN100346777C (zh) 2007-11-07
CA2506962C (en) 2012-01-03
IS7898A (is) 2005-06-20
HRP20050579A2 (hr) 2006-04-30
ATE399543T1 (de) 2008-07-15
EA200500774A1 (ru) 2005-12-29
US20060142308A1 (en) 2006-06-29
EP1567139A1 (en) 2005-08-31
CA2506962A1 (en) 2004-06-10
UA83018C2 (uk) 2008-06-10
MXPA05005437A (es) 2005-08-03
MA27539A1 (fr) 2005-09-01
WO2004047829A8 (en) 2005-06-30
DK1567139T3 (da) 2008-11-03
IL168308A (en) 2010-12-30
SI1567139T1 (sl) 2008-12-31
IS2575B (is) 2010-02-15
ME00489B (me) 2011-10-10
JP2006508994A (ja) 2006-03-16
NO20052999L (no) 2005-06-17
TNSN05131A1 (en) 2007-05-14
HK1081861A1 (en) 2006-05-26
KR20050085104A (ko) 2005-08-29
CN1713903A (zh) 2005-12-28
KR101071798B1 (ko) 2011-10-11
HRP20050579B1 (hr) 2014-01-31
RS51081B (sr) 2010-10-31
PL216752B1 (pl) 2014-05-30
ZA200503308B (en) 2006-11-29
BR0316451A (pt) 2005-10-11
PL377732A1 (pl) 2006-02-06
PT1567139E (pt) 2008-10-01
EA009935B1 (ru) 2008-04-28
EP1567139B1 (en) 2008-07-02

Similar Documents

Publication Publication Date Title
EP1671651B1 (en) Synergistic combination of pumafentrine and salmeterol
KR20050104367A (ko) 타 활성제와 결합하여 장기 효능을 지속하는 베타2-동근으로 구성되는 약물
EP1567139B1 (en) New synergistic combination comprising roflumilast and formoterol
AU2023362721A1 (en) Treatment of idiopathic pulmonary fibrosis with ensifentrine
AU2003288169B2 (en) Synergistic combination comprising roflumilast and (R,R) -formoterol
HK1081861B (en) New synergistic combination comprising roflumilast and formoterol
HK1081862B (en) Synergistic combination comprising roflumilast and (r,r)-formoterol

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: NYCOMED GMBH

Free format text: FORMER NAME: ALTANA PHARMA AG

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE TO READ TAKEDA GMBH .

PC Assignment registered

Owner name: ASTRAZENECA AB

Free format text: FORMER OWNER WAS: TAKEDA GMBH

MK14 Patent ceased section 143(a) (annual fees not paid) or expired